Gene-based immunotherapy for human immunodeficiency virus infection and acquired immunodeficiency syndrome

Human Gene Therapy

Volumn 17, Issue 6, 2006, Pages 577-588

  Dropulic, Boro ^a   June, Carl H ^b  

^a Lentigen Corporation   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALPHA 1 ANTITRYPSIN; ANTIRETROVIRUS AGENT; CD34 ANTIGEN; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; COMPLEMENTARY RNA; CYCLIN T1; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; INTRABODY; LENTIVIRUS VECTOR; RECOMBINANT ANTIBODY; RETROVIRUS VECTOR; REV PROTEIN; RIBOZYME; SHORT HAIRPIN RNA; THYMIDINE KINASE 1; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOPTIVE IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; GENE BASED IMMUNOTHERAPY; GENE THERAPY; GENE TRANSFER; HEMATOPOIETIC STEM CELL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; LONG TERMINAL REPEAT; LYMPHOCYTE DEPLETION; MURINE LEUKEMIA VIRUS; REVIEW; RNA INTERFERENCE; VIRAL GENE THERAPY; VIRUS INTERFERENCE; VIRUS LATENCY; VIRUS REPLICATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; CLINICAL TRIALS; GENE THERAPY; GENETIC VECTORS; HIV INFECTIONS; HUMANS; IMMUNOTHERAPY;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 33745646047     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2006.17.577     Document Type: Review

References (95)

1. AMADO, R.G., MITSUYASU, R.T., ROSENBLATT, J.D., NGOK, F.K., BAKKER, A., COLE, S., CHORN, N., LIN, L.S., BRISTOL, G., BOYD, M.P., MACPHERSON, J.L., FANNING, G.C., TODD, A.V., ELY, J.A., ZACK, J.A., and SYMONDS, G.P. (2004). Anti-human immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a phase I study: Myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients. Hum. Gene Ther. 15, 251-262.
2. AN, D.S., XIE, Y., MAO, S.H., MORIZONO, K., KUNG, S.K.P., and CHEN, I.S.Y. (2003). Efficient lentiviral vectors for short hairpin RNA delivery into human cells. Hum. Gene Ther. 14, 1207-1212.
3. + hematopoietic progenitor cells by a retroviral vector expressing an RRE decoy inhibits human immunodeficiency virus type 1 replication in myelomonocytic cells produced in long-term culture. J. Virol. 70, 4352-4360.
4. BAI, J., SUI, J., ZHU, R.Y., TALLARICO, A.S., GENNARI, F., ZHANG, D., and MARASCO, W.A. (2003). Inhibition of Tat-mediated transactivation and HIV-1 replication by human anti-hCyclinT1 intrabodies. J. Biol. Chem. 278, 1433-1442.
5. BODEN, D., PUSCH, O., LEE, F., TUCKER, L., and RAMRATNAM, B. (2003). Human immunodeficiency virus type 1 escape from RNA interference. J. Virol. 77, 11531-11535.
6. L. Immunity 3, 87-98.
7. BOUHAMDAN, M., STRAYER, D.S., WEI, D., MUKHTAR, M., DUAN, L.X., HOXIE, J., and POMERANTZ, R.J. (2001). Inhibition of HIV-1 infection by down-regulation of the CXCR4 co-receptor using an intracellular single chain variable fragment against CXCR4. Gene Ther. 8, 408-418.
8. BUKOVSKY, A.A., SONG, J.P., and NALDINI, L. (1999). Interaction of human immunodeficiency virus-derived vectors with wild-type virus in transduced cells. J. Virol. 73, 7087-7092.
9. BURNS, J.C., FRIEDMANN, T., DRIEVER, W., BURRASCANO, M., and YEE, J.-K. (1993). Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: Concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc. Natl. Acad. Sci. U.S.A. 90, 8033-8037.
10. CARA, A., RYBAK, S.M., NEWTON, D.L., CROWLEY, R., ROTTSCHAFER, S.E., REITZ, M.S., JR., and GUSELLA, G.L. (1998). Inhibition of HIV-1 replication by combined expression of gag dominant negative mutant and a human ribonuclease in a tightly controlled HIV-1 inducible vector. Gene Ther. 5, 65-75.
11. + T cells. Science 276, 273-276.
12. + cells harboring a human immunodeficiency virus-inducible suicide gene prevents viral spread in an infected cell population. Proc. Natl. Acad. Sci. U.S.A. 89, 182-186.
13. CASE, S.S., PRICE, M.A., JORDAN, C.T., YU, X.J., WANG, L., BAUER, G., HAAS, D.L., XU, D., STRIPECKE, R., NALDINI, L., KOHN, D.B., and CROOKS, G.M. (1999). Stable transduction of quiescent CD34+CD38~ human hematopoietic cells by HIV-1-based lentiviral vectors. Proc. Natl. Acad. Sci. U.S.A. 96, 2988-2993.
14. CHUAH, M.K., VANDENDRIESSCHE, T., CHANG, H.K., ENSOLI, B., and MORGAN, R.A. (1994). Inhibition of human immunodeficiency virus type-1 by retroviral vectors expressing antisense-TAR. Hum. Gene Ther. 5, 1467-1475.
15. COBURN, G.A., and CULLEN, B.R. (2002). Potent and specific inhibition of human immunodeficiency virus type 1 replication by RNA interference. J. Virol. 76, 9225-9231.
16. CORDELIER, P., CALAROTA, S.A., POMERANTZ, R.J., XIAOSHAN, J., and STRAYER, D.S. (2003a). Inhibition of HIV-1 in the central nervous system by IFN-α2 delivered by an SV40 vector. J. Interferon Cytokine Res. 23, 477-488.
17. CORDELIER, P., ZERN, M.A., and STRAYER, D.S. (2003b). HIV-1 proprotein processing as a target for gene therapy. Gene Ther. 10, 467-477.
18. CORDELIER, P., KULKOWSKY, J.W., KO, C., MATSKEVITCH, A.A., MCKEE, H.J., ROSSI, J.J., BOUHAMDAN, M., POMERANTZ, R.J., KARI, G., and STRAYER, D.S. (2004). Protecting from R5-tropic HIV: Individual and combined effectiveness of a hammerhead ribozyme and a single-chain Fv antibody that targets CCR5. Gene Ther. 11, 1627-1637.
19. DAS, A.T., BRUMMELKAMP, T.R., WESTERHOUT, E.M., VINK, M., MADIREDJO, M., BERNARDS, R., and BERKHOUT, B. (2004). Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. J. Virol. 78, 2601-2605.
20. 6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res. 57, 5093-5099.
21. DAVIS, B.M., HUMEAU, L., and DROPULIC, B. (2004). In vivo selection for human and murine hematopoietic cells transduced with a therapeutic MGMT lentiviral vector that inhibits HIV replication. Mol. Ther. 9, 160-172.
22. DEEKS, S.G., WAGNER, B., ANTON, P.A., MITSUYASU, R.T., SCADDEN, D.T., HUANG, C., MACKEN, C., RICHMAN, D.D., CHRISTOPHERSON, C., JUNE, C.H., LAZAR, R., BROAD, D.F., JALALI, S., and HEGE, K.M. (2002). A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. Mol. Ther. 5, 788-797.
23. DEEPANKER TEWARI, A.L.N.P.Z. (2003). Inhibition of HIV-1 replication in primary human T cells transduced with an intracellular anti-HIV-1 p17 antibody gene. J. Gene Med. 5, 182-189.
24. DROPULIC, B., HERMANKOVA, M., and PITHA, P.M. (1996). A conditionally replicating HIV-1 vector interferes with wild-type HIV-1 replication and spread. Proc. Natl. Acad. Sci. U.S.A. 93, 11103-11108.
25. ECKERT, D.M., and KIM, P.S. (2001). Mechanisms of viral membrane fusion and its inhibition. Annu. Rev. Biochem. 70, 777-810.
26. EGELHOFER, M., BRANDENBURG, G., MARTINIUS, H., SCHULT-DIETRICH, P., MELIKYAN, G., KUNERT, R., BAUM, C., CHOI, I., ALEXANDROV, A., and VON LAER, D. (2004). Inhibition of human immunodeficiency virus type 1 entry in cells expressing gp41-derived peptides. J. Virol. 78, 568-575.
27. ELLIS, J. (2005). Silencing and variegation of gammaretrovirus and lentivirus vectors. Hum. Gene Ther. 16, 1241-1246.
28. FEARON, D.T., MANDERS, P., and WAGNER, S.D. (2001). Arrested differentiation, the self-renewing memory lymphocyte, and vaccination. Science 293, 248-250.
29. GONCALVES, J., SILVA, F., FREITAS-VIEIRA, A., SANTA-MARTA, M., MALHO, R., YANG, X., GABUZDA, D., and BARBAS, C., III. (2002). Functional neutralization of HIV-1 Vif protein by intracellular immunization inhibits reverse transcription and viral replication. J. Biol. Chem. 277, 32036-32045.
30. GOODCHILD, J., AGRAWAL, S., CIVEIRA, M.P., SARIN, P.S., SUN, D., and ZAMECNIK, P.C. (1988). Inhibition of human immunodeficiency virus replication by antisense oligodeoxynucleotides. Proc. Natl. Acad. Sci. U.S.A. 85, 5507-5511.
31. HERSCHHORN, A., ADMON, A., and HIZI, A. (2003). Recombinant human antibodies against the reverse transcriptase of human immunodeficiency virus type-1. Biochim. Biophys. Acta 1648, 154-163.
32. + infected patients grouped according to CD4 count and viral load. Mol. Ther. 9, 902-913.
33. KANG, E.M., DE WITTE, M., MALECH, H., MORGAN, R.A., PHANG, S., CARTER, C., LEITMAN, S.F., CHILDS, R., BARRETT, A.J., LITTLE, R., and TISDALE, J.F. (2002). Nonmyeloablative conditioning followed by transplantation of genetically modified HLA-matched peripheral blood progenitor cells for hematologic malignancies in patients with acquired immunodeficiency syndrome. Blood 99, 698-701.
34. KHVOROVA, A., LESCOUTE, A., WESTHOF, E., and JAYASENA, S.D. (2003). Sequence elements outside the hammerhead ribozyme catalytic core enable intracellular activity. Nat. Struct. Biol. 10, 708-712.
35. + cells from the bone marrow of human immunodeficiency virus-1-infected children. Blood 94, 368-371.
36. LALEZARI, J.P., DEJESUS, E., NORTHFELT, D.W., RICHMOND, G., WOLFE, P., HAUBRICH, R., HENRY, D., POWDERLY, W., BECKER, S., THOMPSON, M., VALENTINE, F., WRIGHT, D., CARLSON, M., RIDDLER, S., HAAS, F.F., DEMASI, R., SISTA, P.R., SALGO, M., and DELEHANTY, J. (2003). A controlled phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults. Antivir. Ther. 8, 279-287.
37. LEE, S.W., GALLARDO, H.F., GILBOA, E., and SMITH, C. (1994). Inhibition of human immunodeficiency virus type 1 in human T cells by a potent Rev response element decoy consisting of the 13-nucleotide minimal Rev-binding domain. J. Virol. 68, 8254-8264.
38. + T cells and induce similar patterns of cytokine secretion in vitro. Int. Immunol. 7, 891-904.
39. + T cell proliferation in HIV-positive patients as a result of CD28 costimulation. Science 272, 1939-1943.
40. + T cells in the absence of exogenous feeder cells. J. Immunol. 159, 5921-5930.
41. + T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection. Nat. Med. 8, 47-53.
42. LI, M.J., KIM, J., LI, S., ZAIA, J., YEE, J.K., ANDERSON, J., AKKINA, R., and ROSSI, J.J. (2005). Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy. Mol. Ther. 12, 900-909.
43. LU, X., CHEN, Z., MOLINA, R., REMAMURTHY, P., BINDER, G., and DROPULIC, B. (2004a). Investigations into the relative safety of lentiviral vectors to oncoretroviral vectors. Mol. Ther. 9, 3.
44. LU, X., YU, Q., BINDER, G.K., CHEN, Z., SLEPUSHKINA, T., ROSSI, J., and DROPULIC, B. (2004b). Antisense-mediated inhibition of human immunodeficiency virus (HIV) replication by use of an HIV type 1-based vector results in severely attenuated mutants incapable of developing resistance. J. Virol. 78, 7079-7088.
45. LUCKEY, C.J., BHATTACHARYA, D., GOLDRATH, A.W., WEISSMAN, I.L., BENOIST, C., and MATHIS, D. (2006). Memory T and memory B cells share a transcriptional program of self-renewal with long-term hematopoietic stem cells. Proc. Natl. Acad. Sci. U.S.A. 103, 3304-3309.
46. LUIS ABAD, J., GONZALEZ, M.A., DEL REAL, G., MIRA, E., MANES, S., SERRANO, F., and BERNAD, A. (2003). Novel interfering bifunctional molecules against the CCR5 coreceptor are efficient inhibitors of HIV-1 infection. Mol. Ther. 8, 475-484.
47. LUND, O., LUND, O.S., GRAM, G., NIELSEN, S.D., SCHONNING, K., NIELSEN, J.O., HANSEN, J.E., and MOSEKILDE, E. (1997). Gene therapy of T helper cells in HIV infection: Mathematical model of the criteria for clinical effect. Bull. Math. Biol. 59, 725-745.
48. MACGREGOR, R.R., LEVINE, B.L., LU, X., HUMEAU, L.M., REBELLO, T., MANILLA, P., NI, Y., BINDER, G.K., CARROLL, R., BOYER, J., BUSHMAN, F., SLEPUSHKlN, V., DROPULIC, B., and JUNE, C.H. (2005). Unexpected immune enhancement by autologous lentiviral modified CD4 T cells: Results from a phase I gene transfer trial of lentiviral vector-modified T cells expressing antisense envelope. Presented at the American Society of Gene Therapy 8th Annual Meeting, St. Louis, MO, June 1-5, 2005.
49. + T-lymphocytes in HIV-infected patients. J. Gene Med. 7, 552-564.
50. MALIM, M.H., BOHNLEIN, S., HAUBER, J., and CULLEN, B.R. (1989). Functional dissection of the HIV-1 Rev trans-activator: Derivation of a trans-dominant repressor of Rev function. Cell 58, 205-214.
51. MALIM, M.H., FREIMUTH, W.W., LIU, J., BOYLE, T.J., LYERLY, H.K., CULLEN, B.R., and NABEL, G.J. (1992). Stable expression of transdominant Rev protein in human T cells inhibits human immunodeficiency virus replication. J. Exp. Med. 176, 1197-1201.
52. MANILLA, P., REBELLO, T., AFABLE, C., LU, X., SLEPUSHKIN, V., HUMEAU, L.M., SCHONELY, K., NI, Y., BINDER, G.K., LEVINE, B.L., MACGREGOR, R.R., JUNE, C.H., and DROPULIC, B. (2005). Regulatory considerations for novel gene therapy products: A review of the process leading to the first clinical lentiviral vector. Hum. Gene Ther. 16, 17-25.
53. MITCHELL, R.S., BEITZEL, B.F., SCHRODER, A.R., SHINN, P., CHEN, H., BERRY, C.C., ECKER, J.R., and BUSHMAN, F.D. (2004). Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol. 2, E234.
54. + T cells in human immunodeficiency virus-infected subjects. Blood 96, 785-793.
55. + T lymphocytes engineered with anti-human immunodeficiency virus (HIV) genes in HIV-infected individuals. Hum. Gene Ther. 16, 1065-1074.
56. MORRIS, K.V., and ROSSI, J.J. (2004). Anti-HIV-1 gene expressing lentiviral vectors as an adjunctive therapy for HIV-1 infection. Curr. HIV Res. 2, 185-191.
57. NALDINI, L., BLOMER, U., GALLAY, P., ORY, D., MULLIGAN, R., GAGE, F.H., VERMA, I.M., and TRONO, D. (1996). In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272, 263-267.
58. NEFF, T., HORN, P.A., PETERSON, L.J., THOMASSON, B.M., THOMPSON, J., WILLIAMS, D.A., SCHMIDT, M., GEORGES, G.E., KALLE, C.V., and KIEM, H.-P. (2003). Methylguanine methyltransferase-mediated in vivo selection and chemoprotection of allogeneic stem cells in a large-animal model. J. Clin. Invest., 112, 1581-1588.
59. NOEL, P.J., BOISE, L.H., GREEN, J.M., and THOMPSON, C.B. (1996). CD28 costimulation prevents cell death during primary T cell activation. J. Immunol. 157, 636-642.
60. NOVINA, C.D., MURRAY, M.F., DYKXHOORN, D.M., BERESFORD, P.J., RIESS, J., LEE, S.K., COLLMAN, R.G., LIEBERMAN, J., SHANKAR, P., and SHARP, P.A. (2002). siRNA-directed inhibition of HIV-1 infection. Nat. Med. 8, 681-686.
61. OZ GLEENBERG, I., AVIDAN, O., GOLDGUR, Y., HERSCHHORN, A., and HIZI, A. (2005). Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase. J. Biol. Chem. 280, 21987-21996.
62. + cells. Mol. Ther. 12, 77.
63. POVEDA, E., RODES, B., LABERNARDIERE, J.L., BENITO, J.M., TORO, C., GONZALEZ-LAHOZ, J., FAUDON, J.L., CLAVEL, F., SCHAPIRO, J., and SORIANO, V. (2004). Evolution of genotypic and phenotypic resistance to enfuvirtide in HIV-infected patients experiencing prolonged virologie failure. J. Med. Virol. 74, 21-28.
64. RADVANYI, L.G., SHI, Y., VAZIRI, H., SHARMA, A., DHALA, R., MILLS, G.B., and MILLER, R.G. (1996). CD28 costimulation inhibits TCR-induced apoptosis during a primary T cell response. J. Immunol. 156, 1788-1798.
65. RANGA, U., WOFFENDIN, C., VERMA, S., XU, L., JUNE, C.H., BISHOP, D.K., and NABEL, G.J. (1998). Enhanced T cell engraftment after retroviral delivery of an antiviral gene in HIV-infected individuals. Proc. Natl. Acad. Sci. U.S.A. 95, 1201-1206.
66. + T lymphocytes armed with universal T-cell receptors. Blood 84, 2878-2889.
67. ROE, T., REYNOLDS, T.C., YU, G., and BROWN, P.O. (1993). Integration of murine leukemia virus DNA depends on mitosis. EMBO J. 12, 2099-2108.
68. ROSSI, J.J. (1999). The application of ribozymes to HIV infection. Curr. Opin. Mol. Ther. 1, 316-322.
69. SANHADJI, K., LEISSNER, P., FIROUZI, R., PELLOQUIN, F., KEHRLI, L., MARIGLIANO, M., CALENDA, V., OTTMANN, M., TARDY, J.C., MEHTALI, M., and TOURAINE, J.L. (1997). Experimental gene therapy: The transfer of Tat-inducible interferon genes protects human cells against HIV-1 challenge in vitro and in vivo in severe combined immunodeficient mice. AIDS 11, 977-986.
70. SCZAKTEL, G., OPPENLANDER, M., RITTNER, K., and PAWLITA, M. (1992). Tat- and Rev-directed antisense RNA expression inhibits and abolishes replication of human immunodeficiency virus type 1: A temporal analysis. J. Virol. 66, 5576-5581.
71. SEGAL, D.J., GONCALVES, J., EBERHARDY, S., SWAN, C.H., TORBETT, B.E., LI, X., and BARBAS, C.F., III. (2004). Attenuation of HIV-1 replication in primary human cells with a designed zinc finger transcription factor. J. Biol. Chem. 279, 14509-14519.
72. + T cells. Nat. Med. 9, 727-728.
73. SISTA, P.R., MELBY, T., DAVISON, D., JIN, L., MOSIER, S., MINK, M., NELSON, E.L., DEMASI, R., CAMMACK, N., SALGO, M.P., MATTHEWS, T.J., and GREENBERG, M.L. (2004). Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates. AIDS 18, 1787-1794.
74. STREMLAU, M., OWENS, C.M., PERRON, M.J., KIESSLING, M., AUTISSIER, P., and SODROSKI, J. (2004). The cytoplasmic body component TRIM5α restricts HIV-1 infection in Old World monkeys. Nature 427, 848.
75. SULLENGER, B.A., GALLARDO, H.F., UNGERS, G.E., and GILBOA, E. (1990). Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication. Cell 63, 601-608.
76. SULLENGER, B.A., GALLARDO, H.F., UNGERS, G.E., and GILBOA, E. (1991). Analysis of trans-acting response decoy RNA-mediated inhibition of human immunodeficiency virus type 1 transactivation. J. Virol. 65, 6811-6816.
77. SUN, L.Q., PYATI, J., SMYTHE, J., WANG, L., MACPHERSON, J., GERLACH, W., and SYMONDS, G. (1995). Resistance to human immunodeficiency virus type 1 infection conferred by transduction of human peripheral blood lymphocytes with ribozyme, antisense, or polymeric trans-activation response element constructs. Proc. Natl. Acad. Sci. U.S.A. 92, 7272-7276.
78. TRONO, D., FEINBERG, M.B., and BALTIMORE, D. (1989). HIV-1 Gag mutants can dominantly interfere with the replication of the wild-type virus. Cell 59, 113-120.
79. TSICHLIS, P.N. (1987). Oncogenesis by Moloney murine leukemia virus. Anticancer Res. 7, 171-180.
80. URNOV, F.D., MILLER, J.C., LEE, Y.L., BEAUSEJOUR, C.M., ROCK, J.M., AUGUSTUS, S., JAMIESON, A.C., PORTEUS, M.H., GREGORY, P.D., and HOLMES, M.C. (2005). Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature 435, 646-651.
81. + T lymphocytes by retroviral vectors expressing anti-HIV genes. J. Virol. 69, 4045-4052.
82. + T cell depletion and viral replication in SIV infection. Science 280, 427-431.
83. + lymphocytes. J. Virol. 70, 8792-8800.
84. VERBS, G., JUNKER, U., BAKER, J., BARSKE, C., KALFOGLOU, C., ILVES, H., ESCAICH, S., KANESHIMA, H., and BOHNLEIN, E. (1998). Comparative analyses of intracellularly expressed antisense RNAs as inhibitors of human immunodeficiency virus type 1 replication. J. Virol. 72, 1894-1901.
85. VON LAER, D., VAN LUNZEN, J., GLAUNSINGER, T., HERMANN, F., GIROGLOU, T., NEWRZELA, S., SCHULT-DIETRICH, P., KUEHLCKE, K., JUNE, C.H., BONYHADI, M., and ALEXANDROV, A. (2005). Treatment of HIV Infection with Gene-Protected Autologous T cells. Presented at the 8th Annual Meeting of the American Society of Gene Therapy, June 1-5, 2005, St. Louis, MO.
86. VON LAER, D., HASSELMANN, S., and HASSELMANN, K. (2006). Impact of gene-modified T cells on HIV infection dynamics. J. Theor. Biol. 238, 60-77.
87. WALKER, R.E., BECHTEL, C.M., NATARAJAN, V., BASELER, M., HEGE, K.M., METCALF, J.A., STEVENS, R., HAZEN, A., BLAESE, R.M., CHEN, C.C., LEITMAN, S.F., PALENSKY, J., WITTES, J., DAVEY, R.T., Jr., FALLOON, J., POLIS, M.A., KOVACS, J.A., BROAD, D.F., LEVINE, B.L., ROBERTS, M.R., MASUR, H., and LANE, H.C. (2000). Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. Blood 96, 467-474.
88. WEINBERGER, L.S., SCHAFFER, D.V., and ARKIN, A.P. (2003). Theoretical design of a gene therapy to prevent AIDS but not human immunodeficiency virus type 1 infection. J. Virol. 77, 10028-10036.
89. WENSING, A.M., and BOUCHER, C.A. (2003). Worldwide transmission of drug-resistant HIV. AIDS Rev. 5, 140-155.
90. WENSING, A.M.J., VAN DE VIJVER, D.A., ANGARANO, G., ASJO, B., BALOTTA, C., BOERI, E., CAMACHO, R., CHAIX, M.-L., COSTAGLIOLA, D., DE LUCA, A., DERDELINCKX, I., GROSSMAN, Z., HAMOUDA, O., HATZAKIS, A., HEMMER, R., HOEPELMAN, A., HORBAN, A., KORN, K., KUCHERER, C., LEITNER, T., LOVEDAY, C., MACRAE, E., MALJKOVIC, I., DE MENDOZA, C., MEYER, L., NIELSEN, C., OP DE COUL, E.L., ORMAASEN, V., PARASKEVIS, D., PERRIN, L., PUCHHAMMER-STOCKL, E., RUIZ, L., SALMINEN, M., SCHMIT, J.-C., SCHNEIDER, F., SCHUURMAN, R., SORIANO, V., STANCZAK, G., STANOJEVIC, M., VANDAMME, A.-M., VAN LAETHEM, K., VIOLIN, M., WILBE, K., YERLY, S., ZAZZI, M., BOUCHER, C.A.; SPREAD PROGRAMME. (2005). Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: Implications for clinical management. J. Infect. Dis. 192, 958-966.
91. YANG, B., GAO, L., LI, L., LU, Z., FAN, X., PATEL, C.A., POMERANTZ, R.J., DUBOIS, G.C., and ZHANG, H. (2003). Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins. J. Biol. Chem. 278, 6596-6602.
92. YANG, O.O., TRAN, A.-C., KALAMS, S.A., JOHNSON, R.P., ROBERTS, M.R., and WALKER, B.D. (1997). Lysis of HIV-1-infected cells and inhibition of viral replication by universal receptor T cells. Proc. Natl. Acad. Sci. U.S.A. 94, 11478-11483.
93. YANG, S., SUN, Y., and ZHANG, H. (2001). The multimerization of human immunodeficiency virus type I Vif protein: A requirement for Vif function in the viral life cycle. J. Biol. Chem. 276, 4889-4893.
94. YEE, J.K., FRIEDMANN, T., and BURNS, J.C. (1994). Generation of high-titer pseudotyped retroviral vectors with very broad host range. Methods Cell Biol. 43, 99-112.
95. YUNG, E., SORIN, M., PAL, A., CRAIG, E., MOROZOV, A., DELATTRE, O., KAPPES, J., OTT, D., and KALPANA, G.V. (2001). Inhibition of HIV-1 virion production by a transdominant mutant of integrase interactor 1. Nat. Med. 7, 920-926.